Our results indicated that siSMAD5 significantly reduced the expression levels of the SMAD5 and TGF-βR2 in CD34+ CML cells (Figure 2F, G(Fig. 2)). The gene discussed is SMAD5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.